

## Presentation selected posters

Saturday, September 13, 2008, 15:00 – 16:00 hrs

**Session:** 16 Biomolecular markers/malignant gliomas/quality of life/palliative care  
**Room:** Auditorium  
**Time:** 15:00 - 16:00 hrs  
**Speaking time:** 3´+2´  
**Chair:** K.Hoang Xuan (*France*), G.Reynes (*Spain*)

---

P183

### **MGMT Immunoexpression in Progressive Non-Functioning Pituitary Adenomas: Potential Candidates for Treatment with Temozolomide?**

**G. Widhalm**<sup>1</sup>, S. Wolfsberger<sup>1</sup>, M. Preusser<sup>2</sup>, A. Wöhrer<sup>3</sup>, M. Kotter<sup>1</sup>, T. Czech<sup>1</sup>, C. Maros<sup>2</sup>, E. Knosp<sup>1</sup>;

<sup>1</sup>Department of Neurosurgery, Vienna, Austria, <sup>2</sup>Department of Internal Medicine, Vienna, Austria,

<sup>3</sup>Institute of Neurology, Vienna, Austria.

P190

### **Promoter hypermethylation, Western blotting analysis and immunohistochemistry of MGMT in a series of 101 glioblastomas**

**M. Mellai**<sup>1</sup>, A. Chiò<sup>2</sup>, M. Lanotte<sup>2</sup>, P. Cassoni<sup>3</sup>, V. Caldera<sup>1</sup>, L. Annovazzi<sup>1</sup>, G. Finocchiaro<sup>4</sup>, D. Schiffer<sup>1</sup>;

<sup>1</sup>Neuro-bio-oncology Center Policlinico di Monza Foundation/University of Turin, Vercelli, Italy,

<sup>2</sup>Department of Neuroscience, University of Turin, Turin, Italy, <sup>3</sup>Department of Biomedical Sciences and Human Oncology, University of Turin, Turin, Italy, <sup>4</sup>Fondazione IRCCS, Istituto Neurologico C.Besta, Milan, Italy.

P186

### **Correlation of genomic and epigenomic changes with survival in glioblastoma multiforme**

**P. M. J. Clement**, **A. Wozniak**, H. De Schutter, J. Menten, R. Sciot, F. Van Calenbergh, C. Stefan, M. Debiec-Rychter;

Leuven Cancer Institute, Leuven, Belgium.

P171

### **Phase II study of fixed-dose rate (FDR) gemcitabine as a radiosensitizer for newly diagnosed glioblastoma multiforme (GBM)**

**A. Fabi**, A. M. Mirri, G. Metro, A. Felici, A. Vidiri, A. Pace, M. A. Carosi, F. Cognetti, E. M. Occhipinti, C. M. Carapella;

Regina Elena National Cancer Institute, Rome, Italy.

P172

### **A phase 2 study of multimodal therapy with surgery, carmustine (BCNU) wafer, radiation therapy (RT), and temozolomide (TMZ) in patients (pts) with newly diagnosed supratentorial malignant glioma (MG)**

**R. La Rocca**<sup>1</sup>, T. W. Vitz<sup>2</sup>, W. Villanueva<sup>3</sup>, J. Hodes<sup>4</sup>, A. Cervera<sup>1</sup>, P. New<sup>5</sup>, N. Litofsky<sup>6</sup>, N. Litofsky<sup>6</sup>;

<sup>1</sup>Kentuckiana Cancer Institute, Louisville, KY, United States, <sup>2</sup>Neurosurgical Institute of Kentucky,

Louisville, KY, United States, <sup>3</sup>Louisville Neurological Surgeons, Louisville, KY, United States,

<sup>4</sup>Neurosurgical Associates, Louisville, KY, United States, <sup>5</sup>Baylor College of Medicine, Houston, TX,

United States, <sup>6</sup>University of Missouri University Hospital, Columbia, MO, United States.

Saturday, September 13, 2008, 15:00 – 16:00 hrs

---

P178

**Phase I trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with high grade gliomas.**

**S. A. Grimm<sup>1</sup>**, M. Marymont<sup>1</sup>, J. Chandler<sup>1</sup>, K. Muro<sup>1</sup>, S. Newman<sup>1</sup>, R. Levy<sup>1</sup>, L. Rice<sup>2</sup>, K. Burns<sup>2</sup>, C. Cabreza<sup>2</sup>, J. Raizer<sup>1</sup>;

<sup>1</sup>Northwestern University, Feinberg School of Medicine, Chicago, IL, United States, <sup>2</sup>Northwestern Medical Faculty Foundation, Chicago, IL, United States.

P167

**Evaluation of late toxicity in adult patients treated for medulloblastoma**

**M. M. Sunyach**, C. Christian, F. Didier;

Centre Leon Berard, Lyon, France.

P168

**HADS mood screening in neuro-oncology radiotherapy patients**

**N. B. Detert<sup>1</sup>**, C. Blesing<sup>2</sup>, N. Warner<sup>2</sup>, V. Russell<sup>1</sup>;

<sup>1</sup>John Radcliffe Hospital, Oxford, United Kingdom, <sup>2</sup>Churchill Hospital, Oxford, United Kingdom.

P161

**Neuropsychological and quality of life factors as predictors of survival in patients with glioma**

**A. Bellver-Pérez<sup>1</sup>**, G. Reynes Muntaner<sup>2</sup>, B. Espejo Tort<sup>3</sup>, M. Martín Ureste<sup>4</sup>, J. Montalar Salcedo<sup>5</sup>;

<sup>1</sup>Junta Asociada Provincial de la A.E.C.C. Valencia. Hospital Universitario La Fe., Valencia, Spain, <sup>2</sup>Servicio Oncología Médica. Hospital Universitario La Fe., Valencia, Spain, <sup>3</sup>University of Valencia, Valencia, Spain, <sup>4</sup>Servicio Oncología Médica. Hospital Universitario La Fe., Valencia, Spain, <sup>5</sup>Servicio Oncología Médica. Hospital Universitario La Fe, Valencia, Spain.

**Session: 17 Epidemiology/CNS metastases**

**Room: Sala J**

**Time: 15:00 - 16:00 hrs**

**Speaking time: 3´+2´**

**Chair: W.Grisold (Austria), P.Bilbao (Spain)**

---

P134

**Leptomeningeal carcinomatosis. Prognostic implications of clinical and cerebrospinal fluid features in 70 patients**

**J. Bruna<sup>1</sup>**, L. González<sup>1</sup>, J. Miró<sup>1</sup>, R. Velasco<sup>1</sup>, M. Gil<sup>2</sup>, A. Tortosa<sup>3</sup>;

<sup>1</sup>Institut de Investigació Biomèdica de Bellvitge. Hospital de Bellvitge. Neurology department, Hospitalet del Llobregat, Spain, <sup>2</sup>Hospital Duran i Reynals. Institut Català d'Oncologia. Medical Oncology department, Hospitalet del Llobregat, Spain, <sup>3</sup>Institut de Investigació Biomèdica de Bellvitge. Department of Basic Nursing. Universitat de Barcelona, Hospitalet del Llobregat, Spain.

P138

**Stereotactic Radiosurgery by Helical Tomotherapy System for Metastatic Brain Tumors Using <sup>11</sup>C-methionine PET**

**S. Takenaka<sup>1</sup>**, K. Miwa<sup>1</sup>, J. Shinoda<sup>1</sup>, M. Matsuo<sup>2</sup>, T. Ueda<sup>3</sup>, K. Yokoyama<sup>3</sup>, J. Yamada<sup>3</sup>, H. Yano<sup>4</sup>, T. Iwama<sup>4</sup>;

<sup>1</sup>Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Minokamo, Gifu, Japan, <sup>2</sup>Department of Radio-oncology, Kizawa Memorial Hospital, Minokamo, Gifu, Japan, <sup>3</sup>Department of Neurosurgery, Kizawa Memorial Hospital, Minokamo, Gifu, Japan, <sup>4</sup>Department of Neurosurgery, Gifu University School of Medicine, Gifu, Japan.

Saturday, September 13, 2008, 15:00 – 16:00 hrs

P140

**Brain metastases and radiosurgery : 6 years follow up comparing the RPA , SIR and BSBM patients stratification systems**

**D. Devriendt**<sup>1,2</sup>, F. De Smedt<sup>1,2</sup>, P. David<sup>3</sup>, N. Massager<sup>2</sup>;

<sup>1</sup>Institut Jules Bordet, Brussels, Belgium, <sup>2</sup>Gamma Knife Center of ULB, Brussels, Belgium, <sup>3</sup>Erasmé Hospital, Brussels, Belgium.

P223

**WHO Grade II-III glioma diagnosed before 2000 reclassified in the light of new classification according Immuno-Histo-Chemistry and imaging : a retrospective study of 129 patients.**

**M. Fabbro**<sup>1</sup>, A. Maran<sup>2</sup>, V. Rigau<sup>2</sup>, L. Bauchet<sup>2</sup>, H. Duffau<sup>2</sup>, P. Peray<sup>3</sup>, V. Costes<sup>2</sup>;

<sup>1</sup>CRLC, Montpellier, France, <sup>2</sup>CHU, Montpellier, France, <sup>3</sup>CHU, Nimes, France.

P224

**The impact of changes in pathological classification and referral patterns on treatment and outcome of patients diagnosed with a glioma 1988-2002**

**S. C. Erridge**<sup>1,2</sup>, G. R. Kerr<sup>2</sup>, M. Hart<sup>1</sup>, S. McNamara<sup>1</sup>, C. Smith<sup>1,3</sup>, R. Grant<sup>1</sup>, I. Whittle<sup>1,3</sup>, A. Gregor<sup>1,2</sup>;

<sup>1</sup>Edinburgh Centre for Neuro-Oncology, Edinburgh, United Kingdom, <sup>2</sup>Edinburgh Cancer Centre, Edinburgh, United Kingdom, <sup>3</sup>University of Edinburgh, Edinburgh, United Kingdom.

P225

**Intracranial tumors in a cohort of Neurofibromatosis I patients**

**J. M. de Campos**<sup>1</sup>, M. E. Kusak<sup>2</sup>, C. J. Klein<sup>1</sup>, J. Ayerbe<sup>1</sup>, A. del Villar<sup>3</sup>, J. L. Sarasa<sup>1</sup>;

<sup>1</sup>Fundacion Jiménez Díaz - Universidad Autónoma, Madrid, Spain, <sup>2</sup>H Ruber Internacional, Madrid, Spain, <sup>3</sup>HU Río Hortega, Valladolid, Spain.

P229

**The glioblastoma multiforme of the elderly: the prognostic impact of resection on survival**

**M. Goepfert**, W. Stummer, H. Steiger, M. Sabel;

Department of Neurosurgery, Duesseldorf, Germany.

P237

**Quantifying assessments for glioblastoma multiforme (GBM) for clinical trails - an alternative approach**

**G. Dresemann**<sup>1</sup>, G. Sorenson<sup>2</sup>, D. A. Reardon<sup>3</sup>, C. Hosius<sup>4</sup>, R. Parker<sup>5</sup>, Z. Nikolova<sup>5</sup>;

<sup>1</sup>CTC-Standort Franz-Hospital, Dülmen, Germany, <sup>2</sup>Massachusetts General Hospital, Charlestown, MA, United States, <sup>3</sup>Duke University Medical Center, Durham, NC, United States, <sup>4</sup>Novartis Pharma Oncology, Nürnberg, Germany, <sup>5</sup>Novartis Pharma Oncology, Basel, Switzerland.

P232

**Biodegradable carmustine-impregnated wafers (Gliadel®): the French experience**

**P. Menei**<sup>1</sup>, P. Metellus<sup>2</sup>, H. Loiseau<sup>3</sup>, L. Capelle<sup>4</sup>, G. Jacquet<sup>5</sup>, J. Guyotat and the club of neuro-oncology of the FSN<sup>6</sup>;

<sup>1</sup>CHU d' Angers, Angers, France, <sup>2</sup>Hopital de la Timone, Marseille, France, <sup>3</sup>Hôpital Pellegrin Tripode, Bordeaux, France, <sup>4</sup>Hôpital Pitié Salpêtrière, Paris, France, <sup>5</sup>CHU de Besançon, Besançon, France, <sup>6</sup>Hôpital Neurologique, Lyon, France.

**Session:** 18 Tumor invasion/angiogenesis/in-vitro, in-vivo models  
**Room:** Sala F  
**Time:** 15:00 - 16:00 hrs  
**Speaking time:** 3´+2´  
**Chair:** S.Short (*United Kingdom*), M.Weller (*Germany*)

---

P260

**The influence of Rad51 mediated repair on treatment resistance in high grade gliomas**

S. C. Short<sup>1</sup>, C. Martindale<sup>1</sup>, M. Worku<sup>1</sup>, S. Bourne<sup>2</sup>;

<sup>1</sup>UCL Cancer Institute, London, United Kingdom, <sup>2</sup>University of Oxford, Oxford, United Kingdom.

P246

**Anti-angiogenic compounds cause vessel normalization in gliomas.**

A. Claes, C. Maass, J. W. Jeuken, W. P. Leenders, P. Wesseling;

Dept. of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

P268

**Targeted delivery to primary brain tumors using liposomes**

M. Bellavance, F. Gobeil, D. Fortin;

Sherbrooke University, Sherbrooke, QC, Canada.

P259

**Erucylphosphohomocholine-induced cell death in human glioma cells: Role of the 18 kDa Translocator protein and the ANT2 isoform of the adenine nucleotide transporter**

W. Kugler<sup>1</sup>, P. Hülper<sup>1</sup>, M. Lakomek<sup>1</sup>, M. Gavish<sup>2</sup>, L. Veenman<sup>2</sup>;

<sup>1</sup>Universitäts-Kinderklinik, Göttingen, Germany, <sup>2</sup>Technion-Israel Institute of Technology, Haifa, Israel.

P272

**Autocrine and paracrine contributions of FGF5 to the malignant progression of human astrocytic brain tumors**

S. Allerstorfer<sup>1</sup>, C. Pirker<sup>1</sup>, S. Spiegel-Kreinecker<sup>2</sup>, J. Pichler<sup>3</sup>, J. Buchroithner<sup>2</sup>, M. Grusch<sup>1</sup>, R. Silye<sup>4</sup>, J. Fischer<sup>2</sup>, M. Micksche<sup>1</sup>, W. Berger<sup>1</sup>;

<sup>1</sup>Clinics of Medicine I, Medical University, Vienna, Austria, <sup>2</sup>Department of Neurosurgery, Wagner-Jauregg Hospital, Linz, Austria, <sup>3</sup>Department of Internal Medicine, Wagner-Jauregg Hospital, Linz, Austria, <sup>4</sup>Department of Pathology, Wagner-Jauregg Hospital, Linz, Austria.

P249

**Escape from anti-angiogenic therapy? Phenotypic changes induced by anti-VEGF treatment**

S. J. Grau, J. Thorsteinsdottir, F. Winkler, L. von Baumgarten, J. Tonn, R. H. Goldbrunner;

Grosshadern University Hospital, Munich, Germany.

P253

**Glioma-cell migration on myelinated axons in vitro**

P. Oellers<sup>1</sup>, V. Senner<sup>2</sup>, W. Paulus<sup>3</sup>, S. Thanos<sup>1</sup>;

<sup>1</sup>Department of Experimental Ophthalmology, School of Medicine, Münster, Germany, <sup>2</sup>Institute of Neuropathology, School of Medicine, University Hospital Münster, Münster, Germany, <sup>3</sup>Institute of Neuropathology, School of Medicine, University Hospital Münster, Münster, Germany.

P214

**Towards brain tumour classification by molecular profiling: Imaging, metabolomic and genomic tools**

B. Celda<sup>1</sup>, D. Monleon<sup>2</sup>, J. Piquer<sup>3</sup>, J. Llacer<sup>3</sup>, A. Revert<sup>4</sup>, E. Molla<sup>4</sup>, M. Martinez-Bisbal<sup>1</sup>;

<sup>1</sup>CIBER-BBN- Universitat de Valencia, Burjassot (Valencia), Spain, <sup>2</sup>Fundación Investigación Hospital Clínico Universitario Valencia, Valencia, Spain, <sup>3</sup>Neurosurgery Service Hospital La Ribera, Alzira (Valencia), Spain, <sup>4</sup>Radiology Service Hospital La Ribera, Alzira (Valencia), Spain.

Saturday, September 13, 2008, 15:00 – 16:00 hrs

---

P278

**Circulating adult human mesenchymal stem cells contribute to neoangiogenesis in malignant gliomas**

*C. Schichor*<sup>1</sup>, *I. Teichert von Luettichau*<sup>2</sup>, *B. Krebs*<sup>3</sup>, *S. Grau*<sup>1</sup>, *J. Herms*<sup>3</sup>, *J. Tonn*<sup>1</sup>, *P. Nelson*<sup>4</sup>, ***R. H. Goldbrunner***<sup>1</sup>;

<sup>1</sup>Dept. Neurosurgery, Munich, Germany, <sup>2</sup>Clinical Biochemistry, Dept. Pediatrics, Munich, Germany,

<sup>3</sup>Center for Neuropathology, Munich, Germany, <sup>4</sup>Clinical Biochemistry, Munich, Germany.